Skip to main content
. Author manuscript; available in PMC: 2022 Jan 11.
Published in final edited form as: Pediatr Blood Cancer. 2020 Jan 23;67(5):e28098. doi: 10.1002/pbc.28098

FIGURE 1.

FIGURE 1

FIGURE 1

Four treatment groups were employed: A, control; B, single-agent AZD1775; C, single-agent irinotecan; D, combination of AZD1775 and irinotecan. Doses and schedules are provided in the Methods section. Results are shown for neuroblastoma, osteosarcoma, and Wilms tumor xenograft lines